These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20452542)

  • 1. Is losartan the true panacea for aneurysm disease? CON.
    Danyi P; Jovin IS
    Cardiol Clin; 2010 May; 28(2):279-85. PubMed ID: 20452542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy of thoracic aortic aneurysms.
    Danyi P; Elefteriades JA; Jovin IS
    Trends Cardiovasc Med; 2012 Oct; 22(7):180-4. PubMed ID: 22906366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment: losartan-based medical therapy for aneurysm disease.
    Elefteriades JA
    Cardiol Clin; 2010 May; 28(2):287-8. PubMed ID: 20452543
    [No Abstract]   [Full Text] [Related]  

  • 4. Is losartan the true panacea for aneurysm disease? PRO.
    Collins MJ; Elefteriades JA
    Cardiol Clin; 2010 May; 28(2):273-7. PubMed ID: 20452541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is losartan the drug for all seasons?
    Ramirez F; Rifkin DB
    Curr Opin Pharmacol; 2012 Apr; 12(2):223-4. PubMed ID: 22445547
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
    Hofmann Bowman MA; Eagle KA; Milewicz DM
    JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of Marfan syndrome: a time for change.
    Williams A; Davies S; Stuart AG; Wilson DG; Fraser AG
    Heart; 2008 Apr; 94(4):414-21. PubMed ID: 18347371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.
    Moltzer E; Essers J; van Esch JH; Roos-Hesselink JW; Danser AH
    Pharmacol Ther; 2011 Jul; 131(1):50-60. PubMed ID: 21504760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?
    Matt P; Habashi J; Carrel T; Cameron DE; Van Eyk JE; Dietz HC
    J Thorac Cardiovasc Surg; 2008 Feb; 135(2):389-94. PubMed ID: 18242274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
    Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
    Trials; 2010 Jan; 11():3. PubMed ID: 20067609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
    Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
    Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
    Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
    Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
    De Backer J
    Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
    Plante E; Lachance D; Beaudoin J; Champetier S; Roussel E; Arsenault M; Couet J
    Circ Heart Fail; 2009 Jan; 2(1):25-32. PubMed ID: 19808312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.
    Muiño-Mosquera L; De Nobele S; Devos D; Campens L; De Paepe A; De Backer J
    Acta Cardiol; 2017 Dec; 72(6):616-624. PubMed ID: 28657492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
    Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
    Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties.
    Elefteriades JA; Farkas EA
    J Am Coll Cardiol; 2010 Mar; 55(9):841-57. PubMed ID: 20185035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of angiotensin receptor-1 blockade on electromechanical changes induced by left ventricular hypertrophy and its regression.
    Gray RP; Turner MA; Sheridan DJ; Fry CH
    Cardiovasc Res; 2007 Feb; 73(3):539-48. PubMed ID: 17174288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.